{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:52:27Z","timestamp":1791337947471,"version":"4.3.1"},"reference-count":41,"publisher":"American Diabetes Association","issue":"5","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":3059,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To determine the association between laboratory-derived measures of glycemic control (HbA1c) and the presence of renal complications (measured by proteinuria and estimated glomerular filtration rate [eGFR]) with the 5-year costs of caring for people with diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>We estimated the cumulative 5-year cost of caring for people with diabetes using a province-wide cohort of adults with diabetes as of 1 May 2004. Costs included physician visits, hospitalizations, ambulatory care (emergency room visits, day surgery, and day medicine), and drug costs for people &amp;gt;65 years of age. Using linked laboratory and administrative clinical and costing data, we determined the association between baseline glycemic control (HbA1c), proteinuria, and kidney function (eGFR) and 5-year costs, controlling for age, socioeconomic status, duration of diabetes, and comorbid illness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>We identified 138,662 adults with diabetes. The mean 5-year cost of diabetes in the overall cohort was $26,978 per patient, excluding drug costs. The mean 5-year cost for the subset of people &amp;gt;65 years of age, including drug costs, was $44,511 (Canadian dollars). Cost increased with worsening kidney function, presence of proteinuria, and suboptimal glycemic control (HbA1c &amp;gt;7.9%). Increasing age, Aboriginal status, socioeconomic status, duration of diabetes, and comorbid illness were also associated with increasing cost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>The cost of caring for people with diabetes is substantial and is associated with suboptimal glycemic control, abnormal kidney function, and proteinuria. Future studies should assess if improvements in the management of diabetes, assessed with laboratory-derived measurements, result in cost reductions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc12-0862","type":"journal-article","created":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T22:38:56Z","timestamp":1355438336000},"page":"1172-1180","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":64,"title":["Health Care Costs in People With Diabetes and Their Association With Glycemic Control and Kidney Function"],"prefix":"10.2337","volume":"36","author":[{"given":"Kerry A.","family":"McBrien","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braden J.","family":"Manns","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"},{"name":"Institute for Public Health, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Chui","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Klarenbach","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Rabi","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"},{"name":"Institute for Public Health, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Ravani","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Institute for Public Health, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Hemmelgarn","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"},{"name":"Institute for Public Health, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Wiebe","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Au","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Clement","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"},{"name":"Institute for Public Health, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2013,4,13]]},"reference":[{"key":"2022031220142896900_B1","volume-title":"Diabetes in Canada, 2009","author":"Report from the National Diabetes Surveillance System","year":"2009"},{"key":"2022031220142896900_B2","unstructured":"Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011"},{"key":"2022031220142896900_B3","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(07)60361-4","article-title":"Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study","volume":"369","author":"Lipscombe","year":"2007","journal-title":"Lancet"},{"key":"2022031220142896900_B4","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2337\/dc09-1128","article-title":"Health care and productivity costs associated with diabetic patients with macrovascular comorbid conditions","volume":"32","author":"Fu","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031220142896900_B5","first-page":"1661","article-title":"The cost of major comorbidity in people with diabetes mellitus","volume":"168","author":"Simpson","year":"2003","journal-title":"CMAJ"},{"key":"2022031220142896900_B6","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.2337\/diacare.26.8.2300","article-title":"The direct medical cost of type 2 diabetes","volume":"26","author":"Brandle","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031220142896900_B7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6963-3-7","article-title":"Cost of managing complications resulting from type 2 diabetes mellitus in Canada","volume":"3","author":"O\u2019Brien","year":"2003","journal-title":"BMC Health Serv Res"},{"key":"2022031220142896900_B8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200927060-00004","article-title":"Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis","volume":"27","author":"Pelletier","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"2022031220142896900_B9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2011.06.029","article-title":"Does microvascular disease predict macrovascular events in type 2 diabetes?","volume":"218","author":"Rosenson","year":"2011","journal-title":"Atherosclerosis"},{"key":"2022031220142896900_B10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"2022031220142896900_B11","first-page":"294","article-title":"Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals","volume":"21","author":"Targher","year":"2011","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2022031220142896900_B12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3111\/13696998.2010.548432","article-title":"Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States","volume":"14","author":"Aagren","year":"2011","journal-title":"J Media Econ"},{"key":"2022031220142896900_B13","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.2337\/diacare.20.12.1847","article-title":"The cost to health plans of poor glycemic control","volume":"20","author":"Gilmer","year":"1997","journal-title":"Diabetes Care"},{"key":"2022031220142896900_B14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2337\/diacare.28.1.59","article-title":"Predictors of health care costs in adults with diabetes","volume":"28","author":"Gilmer","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031220142896900_B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1478-7547-4-1","article-title":"The association between diabetes related medical costs and glycemic control: a retrospective analysis","volume":"4","author":"Oglesby","year":"2006","journal-title":"Cost Eff Resour Alloc"},{"key":"2022031220142896900_B16","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc12-s011","article-title":"Standards of medical care in diabetes\u20142012","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031220142896900_B17","first-page":"S1","article-title":"Clinical practice guidelines for the prevention and management of diabetes in Canada","volume":"32","author":"Canadian Diabetes Association","year":"2008","journal-title":"Canadian Journal of Diabetes"},{"key":"2022031220142896900_B18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2369-10-30","article-title":"Overview of the Alberta Kidney Disease Network","volume":"10","author":"Hemmelgarn","year":"2009","journal-title":"BMC Nephrol"},{"key":"2022031220142896900_B19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2337\/diacare.19.8.807","article-title":"Incidence and prevalence of diabetes in Manitoba, 1986-1991","volume":"19","author":"Blanchard","year":"1996","journal-title":"Diabetes Care"},{"key":"2022031220142896900_B20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2337\/diacare.25.3.512","article-title":"Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm","volume":"25","author":"Hux","year":"2002","journal-title":"Diabetes Care"},{"key":"2022031220142896900_B21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1701-2163(16)30194-3","article-title":"Influence of aboriginal and socioeconomic status on birth outcome and maternal morbidity","volume":"24","author":"Johnson","year":"2002","journal-title":"J Obstet Gynaecol Can"},{"key":"2022031220142896900_B22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1472-6963-7-126","article-title":"Health care utilization and costs in Saskatchewan\u2019s registered Indian population with diabetes","volume":"7","author":"Pohar","year":"2007","journal-title":"BMC Health Serv Res"},{"key":"2022031220142896900_B23","unstructured":"Government of Alberta-Health and Wellness. Premium assistance program: premium subsidy [Internet]. Available from http:\/\/www.health.alberta.ca\/AHCIP\/premium-subsidy.html. Accessed 4 April 2011"},{"key":"2022031220142896900_B24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2022031220142896900_B25","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"2022031220142896900_B26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022031220142896900_B27","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2022031220142896900_B28"},{"key":"2022031220142896900_B29"},{"key":"2022031220142896900_B30","author":"Bennett","year":"2011"},{"issue":"4","key":"2022031220142896900_B31","first-page":"CD003418","article-title":"Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus","author":"Goudswaard","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031220142896900_B32","first-page":"e35","article-title":"Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis","volume":"5","author":"McIntosh","year":"2011","journal-title":"Open Med"},{"key":"2022031220142896900_B33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jama.285.2.182","article-title":"Effect of improved glycemic control on health care costs and utilization","volume":"285","author":"Wagner","year":"2001","journal-title":"JAMA"},{"key":"2022031220142896900_B34","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031220142896900_B35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1681\/ASN.2008070667","article-title":"Lowering blood pressure reduces renal events in type 2 diabetes","volume":"20","author":"de Galan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2022031220142896900_B36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7326\/0003-4819-118-2-199301150-00009","article-title":"Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis","volume":"118","author":"Kasiske","year":"1993","journal-title":"Ann Intern Med"},{"key":"2022031220142896900_B37","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2022031220142896900_B38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031220142896900_B39","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031220142896900_B40","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"2022031220142896900_B41","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1681\/ASN.2005121337","article-title":"Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression","volume":"17","author":"Strippoli","year":"2006","journal-title":"J Am Soc Nephrol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/5\/1172\/616950\/1172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/5\/1172\/616950\/1172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T17:03:19Z","timestamp":1647104599000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/36\/5\/1172\/29802\/Health-Care-Costs-in-People-With-Diabetes-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,13]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,4,13]]},"published-print":{"date-parts":[[2013,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc12-0862","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,13]]}}}